ATE247717T1 - Apoliporotein e polymorphismen und behandlung der alzheimerkrankheit - Google Patents
Apoliporotein e polymorphismen und behandlung der alzheimerkrankheitInfo
- Publication number
- ATE247717T1 ATE247717T1 AT95916530T AT95916530T ATE247717T1 AT E247717 T1 ATE247717 T1 AT E247717T1 AT 95916530 T AT95916530 T AT 95916530T AT 95916530 T AT95916530 T AT 95916530T AT E247717 T1 ATE247717 T1 AT E247717T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- apoliporotein
- polymorphisms
- alzheimer
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9408465A GB9408465D0 (en) | 1994-04-27 | 1994-04-27 | Apolipoprotein e polymorphism & treatment of alzheimer's disease |
PCT/CA1995/000240 WO1995029257A2 (en) | 1994-04-27 | 1995-04-26 | Apolipoprotein e polymorphism and treatment of alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE247717T1 true ATE247717T1 (de) | 2003-09-15 |
Family
ID=10754293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT95916530T ATE247717T1 (de) | 1994-04-27 | 1995-04-26 | Apoliporotein e polymorphismen und behandlung der alzheimerkrankheit |
Country Status (13)
Country | Link |
---|---|
US (1) | US5935781A (de) |
EP (1) | EP0804615B1 (de) |
JP (1) | JP3285585B2 (de) |
AT (1) | ATE247717T1 (de) |
AU (1) | AU693193B2 (de) |
CA (1) | CA2188933C (de) |
DE (1) | DE69531557T2 (de) |
FI (1) | FI964284A (de) |
GB (1) | GB9408465D0 (de) |
MX (1) | MX9605176A (de) |
NO (1) | NO964543L (de) |
NZ (1) | NZ284412A (de) |
WO (1) | WO1995029257A2 (de) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7049078B2 (en) * | 1994-04-27 | 2006-05-23 | Judés Poirier | Apolipoprotein E polymorphism and treatment of alzheimer's disease |
GB9408465D0 (en) * | 1994-04-27 | 1994-06-22 | Univ Mcgill | Apolipoprotein e polymorphism & treatment of alzheimer's disease |
US6022683A (en) * | 1996-12-16 | 2000-02-08 | Nova Molecular Inc. | Methods for assessing the prognosis of a patient with a neurodegenerative disease |
US5767337A (en) * | 1995-07-31 | 1998-06-16 | Duke University | Creation of human apolipoprotein E isoform specific transgenic mice in apolipoprotein deficient "knockout" mice |
GB9525481D0 (en) * | 1995-12-13 | 1996-02-14 | Royston M C | Novel method |
ES2115553B1 (es) * | 1996-10-23 | 1999-02-16 | Boehringer Ingelheim Espana | Metodo para detectar la presencia de polimorfismos de dna, estuche de ensayo y acidos nucleicos recombinantes correspondientes. |
FR2765591B1 (fr) * | 1997-07-01 | 2002-08-09 | Pasteur Institut | Procede de diagnostic de la maladie d'alzheimer |
CA2304505A1 (en) * | 1997-09-24 | 1999-04-01 | Nova Molecular, Inc. | Methods for increasing apoe levels for the treatment of neurodegenerative disease |
ES2142248B1 (es) * | 1997-11-20 | 2000-11-16 | Univ Madrid Autonoma | Polimorfismos en el promotor del gen humano de la apolipoproteina e, y sus usos para aplicaciones diagnosticas y terapeuticas. |
US6251587B1 (en) | 1997-12-16 | 2001-06-26 | Nova Molecular, Inc. | Method for determining the prognosis of a patient with a neurological disease |
WO1999058640A2 (en) | 1998-05-11 | 1999-11-18 | Philadelphia Health And Education Corporation | Mct-1, a human oncogene |
EP1117840A1 (de) | 1998-10-01 | 2001-07-25 | Variagenics, Inc. | Verfahren zur erkennung oder behandlung von personen mit einem risiko für neuronale erkrankungen durch die bestimmung von gpiiia or gpiib allelvarianten |
US20040209849A1 (en) * | 1998-11-27 | 2004-10-21 | Sanochemia Pharmazeutika Aktiengesellschaft | Use of effectors of the central cholinergic nervous system for treatment of delirium |
US6573049B1 (en) | 1999-07-26 | 2003-06-03 | Nuvelo, Inc. | Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease |
US6432643B1 (en) * | 1999-10-22 | 2002-08-13 | Duke University | Method of determining Alzheimer's disease risk using apolipoprotein E4 genotype analysis in combination with decreased estrogen levels |
EP1113081A1 (de) * | 1999-12-28 | 2001-07-04 | Institut Pasteur De Lille | Zusammenhang des bekannten Gens CP2/LSF/LBP-1 mit Alzheimer |
US6453244B1 (en) * | 2000-02-10 | 2002-09-17 | Stanford University | Detection of polymorphisms by denaturing high-performance liquid chromatography |
US20030208454A1 (en) * | 2000-03-16 | 2003-11-06 | Rienhoff Hugh Y. | Method and system for populating a database for further medical characterization |
US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
DE60138019D1 (de) * | 2000-05-01 | 2009-04-30 | Accera Inc | Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung |
US20020010552A1 (en) * | 2000-05-26 | 2002-01-24 | Hugh Rienhoff | System for genetically characterizing an individual for evaluation using genetic and phenotypic variation over a wide area network |
AU2002237847A1 (en) * | 2001-02-12 | 2002-08-28 | Akzo Nobel N.V | Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4 |
US20030105082A1 (en) * | 2001-12-03 | 2003-06-05 | Murphy Greer Marechal | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
US6399310B1 (en) | 2001-02-12 | 2002-06-04 | Akzo Nobel N.V. | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
US20040005566A1 (en) * | 2002-07-02 | 2004-01-08 | Genelink, Inc. | Kits and methods for assessing cardiovascular health |
JP5064216B2 (ja) | 2004-07-16 | 2012-10-31 | プロテオシス・アーゲー | 炎症性疾患用治療剤としての、parp及びsir調節活性を有するムスカリンアンタゴニスト |
EP2001293B9 (de) * | 2006-04-03 | 2019-04-17 | Accera, Inc. | Verwendung ketogener verbindungen zur behandlung altersbedingter gedächtnisschwächen |
US20080249103A1 (en) * | 2006-11-15 | 2008-10-09 | Sirtris Pharmaceuticals, Inc. | Sirtuin polymorphisms and methods of use thereof |
EP2650381B1 (de) | 2007-07-31 | 2016-09-21 | Accera, Inc. | Verwendung genomischer und ketogener Verbindungen zur Behandlung von beeinträchtigten kognitiven Funktionen |
US8105809B2 (en) * | 2008-07-03 | 2012-01-31 | Accera, Inc. | Enzymatic synthesis of acetoacetate esters and derivatives |
CN102105071A (zh) * | 2008-07-03 | 2011-06-22 | 艾克塞拉公司 | 用于治疗神经性障碍的乙酰乙酸的单甘油酯及其衍生物 |
WO2010081825A2 (en) | 2009-01-13 | 2010-07-22 | Proteosys Ag | Pirenzepine as an agent in cancer treatment |
US20110177061A1 (en) | 2009-07-10 | 2011-07-21 | Martek Biosciences Corporation | Methods of treating and preventing neurological disorders using docosahexaenoic acid |
WO2018112446A2 (en) * | 2016-12-18 | 2018-06-21 | Selonterra, Inc. | Use of apoe4 motif-mediated genes for diagnosis and treatment of alzheimer's disease |
EP3628315A1 (de) | 2018-09-28 | 2020-04-01 | Université de Caen Normandie | Kombination aus acetylcholinesterase-inhibitor und 5-ht4-rezeptoragonist als neuroprotektives mittel zur behandlung von neurodegenerativen krankheiten |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE262592T1 (de) * | 1992-10-13 | 2004-04-15 | Univ Duke | Verfahren zum nachweis der alzheimer krankheit |
WO1995003052A1 (en) * | 1993-07-22 | 1995-02-02 | Warner-Lambert Company | Controlled release tacrine drug delivery systems and methods for preparing same |
US5643960A (en) * | 1994-04-15 | 1997-07-01 | Duke University | Method of delaying onset of alzheimer's disease symptoms |
GB9408465D0 (en) * | 1994-04-27 | 1994-06-22 | Univ Mcgill | Apolipoprotein e polymorphism & treatment of alzheimer's disease |
US5698224A (en) * | 1994-06-27 | 1997-12-16 | Alza Corporation | Tacrine therapy |
GB9415073D0 (en) * | 1994-06-27 | 1994-09-14 | Smithkline Beecham Plc | Novel method |
GB9414624D0 (en) * | 1994-07-20 | 1994-09-07 | Smithkline Beecham Plc | Novel method |
-
1994
- 1994-04-27 GB GB9408465A patent/GB9408465D0/en active Pending
-
1995
- 1995-04-26 NZ NZ284412A patent/NZ284412A/xx not_active IP Right Cessation
- 1995-04-26 CA CA002188933A patent/CA2188933C/en not_active Expired - Fee Related
- 1995-04-26 AU AU23006/95A patent/AU693193B2/en not_active Ceased
- 1995-04-26 US US08/727,637 patent/US5935781A/en not_active Expired - Lifetime
- 1995-04-26 WO PCT/CA1995/000240 patent/WO1995029257A2/en active IP Right Grant
- 1995-04-26 EP EP95916530A patent/EP0804615B1/de not_active Expired - Lifetime
- 1995-04-26 AT AT95916530T patent/ATE247717T1/de not_active IP Right Cessation
- 1995-04-26 DE DE69531557T patent/DE69531557T2/de not_active Expired - Lifetime
- 1995-04-26 JP JP52724895A patent/JP3285585B2/ja not_active Expired - Fee Related
-
1996
- 1996-10-24 FI FI964284A patent/FI964284A/fi not_active IP Right Cessation
- 1996-10-25 NO NO964543A patent/NO964543L/no not_active Application Discontinuation
- 1996-10-28 MX MX9605176A patent/MX9605176A/es not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2300695A (en) | 1995-11-16 |
WO1995029257A3 (en) | 1995-11-23 |
NO964543D0 (no) | 1996-10-25 |
CA2188933A1 (en) | 1995-11-02 |
CA2188933C (en) | 2000-11-14 |
JP3285585B2 (ja) | 2002-05-27 |
US5935781A (en) | 1999-08-10 |
NZ284412A (en) | 2000-01-28 |
GB9408465D0 (en) | 1994-06-22 |
DE69531557D1 (de) | 2003-09-25 |
AU693193B2 (en) | 1998-06-25 |
NO964543L (no) | 1996-12-20 |
EP0804615A1 (de) | 1997-11-05 |
EP0804615B1 (de) | 2003-08-20 |
DE69531557T2 (de) | 2004-06-17 |
WO1995029257A2 (en) | 1995-11-02 |
FI964284A (fi) | 1996-12-23 |
FI964284A0 (fi) | 1996-10-24 |
JPH10500288A (ja) | 1998-01-13 |
MX9605176A (es) | 1998-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE247717T1 (de) | Apoliporotein e polymorphismen und behandlung der alzheimerkrankheit | |
DE69729473D1 (de) | Pharmazeutisch-genetische verfahren zur verwendung bei der behandlung von krankheiten des nervensystems | |
Holmes et al. | Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease. | |
LV12558A (lv) | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate | |
AU8132194A (en) | Single nucleotide polymorphisms and their use in genetic analysis | |
DE69513167T2 (de) | Perfluoroalkyll ketone, inhibitoren von elastase und prozess zur deren herstellung | |
DE69526120T2 (de) | Verwendung von nebivolol als anti-atherogenisches mittel | |
ATE198050T1 (de) | Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia | |
NO961478L (no) | Levobupivacaine anvendelig for kontroll av kronisk smerte | |
Steinlein et al. | Neuronal nicotinic acetylcholine receptor α4 subunit (CHRNA4) and panic disorder: An association study | |
EP0830139A4 (de) | Modifizierte myelin proteinmoleküle | |
DE69705936D1 (de) | Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose | |
ATE253117T1 (de) | Adenovirus e4 proteine für induktion von zelltod | |
Raza et al. | A novel homozygous nonsense mutation in the PVRL4 gene and expansion of clinical spectrum of EDSS1 | |
GB9610281D0 (en) | Diagnostic method and apparatus | |
WO1997042347A3 (en) | 5-lipoxygenase gene polymorphisms and their use in classifying patients | |
DE59509370D1 (de) | Mittel zur beeinflussung von störungen der knochenbildung, das kaliumcitrate und/oder kaliumlactate und/oder kaliummalate enthält | |
ATE225405T1 (de) | Verfahren zur diagnose oder zur prognose von alzheimer krankheit: therapeutische zusammensetzung zur verhinderung oder zur behandlung von alzheimer krankheit | |
NZ228068A (en) | Brominated or chlorinated allylamines and their pharmaceutical compositions | |
AU2002358580A1 (en) | Methods of identifying genetic risk for and evaluating treatment of alzheimer's disease by determing single nucleotide polymorphisms | |
DE60224778D1 (de) | Zusammensetzungen und Verfahren zur Behandlung und zur Detektion von proliferativen Störungen die mit der Überexpression des menschlichen "Transketolase like-1" gens in Zusammenhang stehen | |
Hashimoto et al. | Association analysis between schizophrenia and the AP-3 complex genes | |
Akar et al. | Factor V 1691G-A mutation and high factor VIII levels in a patient with intracardiac thrombosis | |
AU5052599A (en) | Genetic polymorphisms in the human neurokinin 2 receptor gene and their use in diagnosis and treatment of diseases | |
DE69928814D1 (de) | Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |